Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New asian registry aims to improve cervical cancer radiation treatment

NCT ID NCT07196033

Knowledge-focused Sponsor: Tata Memorial Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study is creating a registry to collect information from hospitals across Asia on how brachytherapy (internal radiation) is used to treat cervical cancer. The goal is to understand current practices, track outcomes, and find ways to improve care for women with this disease. About 1,000 women with stage IB to IVA cervical cancer who are scheduled for radiation and chemotherapy will have their treatment data recorded.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 1,000 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Feb 2026

An estimate. Start dates often move.

Expected to finish

May 2028

An estimate. End dates often move.

Lead sponsor

A government agency

The lead sponsor is a government body.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

The study population is diagnosed with FIGO 2018 stage IB-IVA cervical cancer with squamous cell carcinoma, adenocarcinoma or adenosquamous carcinoma histological subtype and have undergone treatment with definitive chemo-radiation and brachytherapy (X-ray, CT, CT-Ultrasound or MRI based) for cervical cancer.

Ages

Children (under 18), adults (18 to 64) and older adults (65 and over)

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients diagnosed with FIGO 2018 stage IB-IVA cervical cancer with squamous cell carcinoma, adenocarcinoma or adenosquamous carcinoma histological subtype. * Planned for treatment with definitive chemo-radiation and brachytherapy. (X- ray,CT, CT-Ultrasound or MRI based). Exclusion Criteria: * Neuroendocrine cancer of the cervix or other rare histology subtypes. * Patients with metastatic cervix cancer and not planned for radical doses of pelvic RT/brachytherapy may be excluded. * Patients undergoing postoperative RT or RT for recurrent disease should be excluded.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Stage IB cervical cancer figo 2018 are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

cervical cancer cervical carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Stage IB cervical cancer figo 2018 Stage IIA cervical cancer figo 2018 Stage IIB cervical cancer figo 2018 Stage IIIA cervical cancer figo 2018 Stage IIIB cervical cancer figo 2018 Stage IVA cervical cancer figo 2018

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    5 sites in 3 countries. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Chiang Mai University

    NOT_YET_RECRUITING

    Chiang Mai, Thailand, Thailand

  • Gunma University

    NOT_YET_RECRUITING

    Maebashi, Japan, Japan

  • Juntendo University

    NOT_YET_RECRUITING

    Tokyo, Japan, Japan

  • Mahidol University

    NOT_YET_RECRUITING

    Bangkok, Thailand, Thailand

  • Tata Memorial Center

    RECRUITING

    Mumbai, Maharashtra, 400012, India

More trials for these conditions

Other studies related to the condition(s) this trial covers.